Massachusetts Institute of Technology and Sigilon Therapeutics, Inc. FIFTH AMENDMENTExclusive Patent License Agreement • November 10th, 2021 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This Fifth Amendment (“Fifth Amendment”), effective as of September 17, 2021 (the “Fifth Amendment Effective Date”), is made by and between the Massachusetts Institute of Technology, a nonprofit research institution having a principal address at 77 Massachusetts Avenue, Cambridge, MA 02139 (“MIT”) and Sigilon Therapeutics, Inc. (fka Sigilon, Inc.) a Delaware corporation, having a principal address at 100 Binney Street, Cambridge, MA 02142 (“Company”) (each individually a “Party” and collectively the “Parties”), and amends that certain Exclusive Patent License Agreement between the Parties dated as of February 8, 2016, as amended (collectively, the “License Agreement”). Capitalized terms used herein without definition shall have the meaning given such terms in the License Agreement.
